Imaging breast cancer bone metastases: Current status and future directions

Seminars in Nuclear Medicine

Volumn 43, Issue 4, 2013, Pages 317-323

  Glendenning, Jennifer ^a,c   Cook, Gary ^b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETIDRONIC ACID TC 99M; FLUORINE 18; FLUORODEOXYGLUCOSE F 18;

ARTICLE; BONE ATROPHY; BONE DEVELOPMENT; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL PRACTICE; DIAGNOSTIC IMAGING; DISEASE COURSE; FUNCTIONAL STATUS; HUMAN; META ANALYSIS (TOPIC); MORBIDITY; POSITRON EMISSION TOMOGRAPHY; PROTEIN SYNTHESIS; QUALITY OF LIFE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINAL CORD COMPRESSION; SYSTEMIC THERAPY; TREATMENT RESPONSE;

BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS;

EID: 84878365715     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2013.02.002     Document Type: Article

References (56)

1. T.A. Plunkett, P. Smith, and R.D. Rubens Risk of complications from bone metastases in breast cancer: Implications for management Eur J Cancer 36 2000 476 482
2. S. Wei, Y. Li, and G.P. Siegal Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs Ann Diagn Pathol 15 2011 79 83
3. S. Jung, M. Rosenzweig, and S. Sereika Factors associated with mortality after breast cancer metastasis Cancer Causes Control 23 2012 103 112
4. K. Manders, L. van de Poll-Franse, and G.-J. Creemers Clinical management of women with metastatic breast cancer: A descriptive study according to age group BMC Cancer 6 2006 179
5. N. Sathiakumar, E. Delzell, and M. Morrisey Mortality following bone metastasis and skeletal-related events among women with breast cancer: A population-based analysis of U.S. Medicare beneficiaries, 1999-2006 Breast Cancer Res Treat 131 2012 231 238
6. S.M. Domchek, J. Younger, and D.M. Finkelstein Predictors of skeletal complications in patients with metastatic breast carcinoma Cancer 89 2000 363 368
7. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
8. J.L. Hayward, P.P. Carbone, and J.C. Heusen Assessment of response to therapy in advanced breast cancer Br J Cancer 35 1977 292 298
9. WHO Handbook for Reporting Results of Cancer Treatment. Geneva (Switzerland): World Health Organisation Offset Publication no. 48; 1979
10. T. Hamaoka, C.M. Costelloe, and J.E. Madewell Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer Br J Cancer 102 2010 651 657
11. National Institute for Health and Clinical Excellence (NICE). Advanced breast cancer - Diagnosis and treatment. Clinical Guideline 81, 2009. http://www.nice.org.uk
12. National Comprehensive Cancer Network Breast Cancer Guideline, version 1, 2012. http://www.nccn.org2012
13. P. Shie, C. Cardarelli, and D. Brandon Meta-analysis:Comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with breast cancer Clin Nucl Med 33 2008 97 101
14. Y. Du, I. Cullum, and T.M. Illidge Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer J Clin Oncol 25 2007 3440 3447
15. R.E. Coleman, G. Mashiter, and K.B. Whitaker Bone scan flare predicts successful systemic therapy for bone metastases J Nucl Med 29 1988 1354 1359
16. H.C. Thoeny, and B.D. Ross Predicting and monitoring cancer treatment response with diffusion-weighted MRI J Magn Reson Imaging 32 2010 2 16
17. T.E. Yankeelov, M. Lepage, and A. Chakravarthy Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results Magn Reson Imaging 25 2007 1 13
18. E. Rubesova, A.-S. Grell, and V. De Maertelaer Quantitative diffusion imaging in breast cancer: A clinical prospective study J Magn Reson Imaging 24 2006 319 324
19. U. Sharma, K.K.A. Danishad, and V. Seenu Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy NMR Biomed 22 2009 104 113
20. A. Fangberget, L. Nilsen, and K. Hole Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging Eur Radiol 21 2011 1188 1199
21. M.D. Pickles, P. Gibbs, and M. Lowry Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer Magn Reson Imaging 24 2006 843 847
22. C. Reischauer, J.M. Froehlich, and D.-M. Koh Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps - Initial observations Radiology 257 2010 523 531
23. K.C. Lee, D.A. Bradley, and M. Hussein A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone Neoplasia 9 2007 1003 1011
24. R. Bos, J.J.M. van der Hoeven, and E. van der Wall Biologic correlates of 18Fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography J Clin Oncol 20 2002 379 387
25. A. Buck, H. Schirrmeister, and T. Kuhn FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters Eur J Nucl Med 29 2002 1317 1323
26. J. Tchou, S. Sonnad, and M. Bergey Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer Mol Imaging Biol 12 2010 657 662
27. B. Keam, S. Im, and H. Koh Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy BMC Cancer 11 2011 doi:10.1186/147-2407-11-452 [published online]
28. A. Gil-Rendo, F. Martínez-Regueira, and G. Zornoza Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer Br J Surg 96 2009 166 170
29. G.J. Cook, S. Houston, and R. Rubens Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions J Clin Oncol 16 1998 3375 3379
30. T. Nakai, C. Okuyama, and T. Kubota Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer Eur J Nucl Med Mol Imaging 32 2005 1253 1258
31. 99mTc-HMBP scintigraphy for the detection of bone metastasis in patients with breast cancer Ann Nucl Med 19 2005 573 579
32. B. Koolen, E. Vegt, and E. Rutgers FDG-avid sclerotic bone metastases in breast cancer patients: A PET/CT case series Ann Nucl Med 26 2012 86 91
33. S. Hahn, T. Heusner, and S. Kümmel Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer Acta Radiologica 52 2011 1009 1014
34. W. Wang, C. Zhang, and J. Liu Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis Breast Cancer Res Treat 131 2012 357 369
35. J. Dose Schwarz, M. Bader, and L. Jenicke Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET J Nucl Med 46 2005 1144 1150
36. U. De Giorgi, M. Mego, and E.M. Rohren 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer J Nucl Med 51 2010 1213 1218
37. J. Specht, S. Tam, and B. Kurland Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP) Breast Cancer Res Treat 105 2007 87 94
38. U. Tateishi, C. Gamez, and S. Dawood Bone Metastases in patients with metastatic breast cancer: Morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT Radiology 247 2008 189 196
39. T. Katayama, K. Kubota, and Y. Machida Evaluation of sequential FDG-PET/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumor markers Ann Nucl Med 26 2012 426 435
40. K.R. Hess, L. Pusztai, and A.U. Buzdar Estrogen receptors and distinct patterns of breast cancer relapse Breast Cancer Res Treat 78 2003 105 118
41. N. Mortazavi-Jehanno, A.L. Giraudet, and L. Champion Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: A pilot study Eur J Nucl Med Mol Imaging 39 2012 450 460
42. H. Young, R. Baum, and U. Cremerius Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations Eur J Cancer 35 1999 1773 1782
43. M. Petren-Mallmin, I. Andreasson, and O. Ljunggren Skeletal metastasis from breast cancer: Uptake of 18F-fluoride measured with positron emission tomography in correlation with CT Skeletal Radiol 27 1998 72 76
44. H. Schirrmeister, A. Guhlmann, and J. Kotzerke Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography J Clin Oncol 17 1999 2381
45. E. Even-Sapir, U. Metser, and G. Flusser Assessment of malignant skeletal disease: Initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT J Nucl Med 45 2004 272 278
46. 18F-FDG PET/CT Eur J Nucl Med Mol Imaging 36 2009 1807 1812
47. R.K. Doot, M. Muzi, and L.M. Peterson Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastasis J Nucl Med 51 2010 521 527
48. 223Ra-chloride (Alpharadin) EJNMMI Res 1 2011 4
49. C. Liedtke, c Mazouni, and K.R. Hess Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 2008 1275 1281
50. M. Smid, Y. Wang, and J.G.M. Klijn Genes associated with breast cancer metastatic to bone J Clin Oncol 24 2006 2261 2267
51. M. Smid, Y. Wang, and Y. Zhang Subtypes of breast cancer show preferential site of relapse Cancer Res 68 2008 3108 3114
52. H. Kennecke, R. Yerushalmi, and R. Woods Metastatic behavior of breast cancer subtypes J Clin Oncol 28 2010 3271 3277
53. L.M. Peterson, D.A. Mankoff, and T. Lawton Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol J Nucl Med 49 2008 367 374
54. M. van Kruchten, A.W.J.M. Glaudemans, and E.F.J. de Vries PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma J Nucl Med 53 2012 182 190
55. J.E. Mortimer, F. Dehdashti, and B.A. Siegel Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer J Clin Oncol 19 2001 2797 2803
56. F. Dehdashti, J. Mortimer, and K. Trinkaus PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer Breast Cancer Res Treat 113 2009 509 517